Hangzhou Hertz Pharmaceutical Co. Ltd.’s Pan-RAS molecular glue HZ-V055 clinical trial application has been accepted

RAS is one of the most frequently mutated genes in human cancers. As an important member of the small GTPase family, RAS proteins act as “molecular switches,” cycling between the GTP-bound “ON” active state and the GDP-bound “OFF” inactive state. When RAS genes are mutated, the RAS protein loses its ability to hydrolyze GTP and becomes permanently locked in the “ON” state, continuously driving abnormal cell proliferation and ultimately leading to tumorigenesis.

HZ-V055 is a Pan-RAS (ON) inhibitor newly designed and developed using Hangzhou Hertz Pharmaceutical Co. Ltd.’s internal molecular glue technology platform. It directly targets the GTP-bound (ON) state of RAS proteins. The drug selectively binds to endogenous cyclophilin A (CypA) in cells, forming a CypA/inhibitor/RAS ternary complex that sterically blocks the interaction between RAS and downstream effector proteins (such as RAF and PI3K), thereby effectively inhibiting the activation of oncogenic signaling pathways.

HZ-V055 is jointly developed by Hangzhou Hertz Pharmaceutical Co. Ltd. and the Chinese Academy of Sciences Shanghai Institute of Materia Medica. The acceptance of its clinical trial application marks a critical step forward for Hangzhou Hertz Pharmaceutical Co. Ltd. in the field of solid tumors, particularly gastrointestinal cancers. The company is accelerating the clinical development of this product, continuously exploring its therapeutic potential in various RAS-mutant tumors, and actively investigating combination with other therapies, striving to benefit patients as soon as possible.